Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 6

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 6
---
 comply with regulation by various federal, state, local and foreign governmental agencies and to maintain necessary 
 regulatory clearances or approvals;                                                                                                |

| ● | our ability to maintain compliance with Nasdaq listing standards; |

| ● | our ability to successfully adopt and execute on our new digital asset treasury strategy; |

| ● | risks related to regulatory developments regarding digital assets and digital asset markets, which could adversely affect our business, 
 financial condition, and results of operations;                                                                                         |

| ● | the volatile and unpredictable cycles in the digital asset industry; |

| ● | any changes in the accounting treatment of digital assets; |

| ● | our dependence on our senior management team; and |

| ● | the other risks and uncertainties described in the Risk Factors section of this prospectus supplement, any additional prospectus supplement     
 and our most recent Annual Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, which filings are incorporated herein by reference. |

We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. All subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the applicable cautionary statements. We further caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

<div align='center'>S-3

THE COMPANY</div>

This summary highlights information contained in other parts of this prospectus supplement and in the documents we incorporate by reference. Because it is only a summary, it does not contain all of the information that you should consider before investing in our common stock and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere or incorporated by reference in this prospectus supplement. You should read all such documents carefully, especially the risk factors and our consolidated financial statements and the related notes included or incorporated by reference in this prospectus supplement, before deciding to buy shares of our common stock.

Overview

We were incorporated as a Delaware corporation
in 2007. Currently, we are developing a next-generation enhanced ultrasound technology platform-Thermo-Acoustic Enhanced Ultrasound,
or TAEUS. Our first TAEUS platform application focuses on measuring fat in the liver. Additionally, we recently launched